# A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

> **NCT04047251** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Fujifilm Pharmaceuticals U.S.A., Inc.** · enrollment: 96 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Merkel Cell Carcinoma

## Interventions

- **DRUG:** FF-10850 Topotecan Liposome Injection

## Key facts

- **NCT ID:** NCT04047251
- **Lead sponsor:** Fujifilm Pharmaceuticals U.S.A., Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-14
- **Primary completion:** 2025-12
- **Final completion:** 2026-07
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047251, "A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04047251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*